Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. The Chinese biotech ticked the publication of multiple ascending dose data off its to-do list Wednesday, linking its oral GLP-1 prospect to 6.3% mean body weight loss after 28 days.
Ascletis announced (PDF) its entry into the…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Employees Spend Up to $1,500 Out of Pocket as Employer Benefits Miss the Mark, Castlight Survey Finds
36% seek their own tools first and nearly half use consumer health apps as static, hard‑to‑navigate benefits fail to keep pace with employee needs SANDY, Utah, April 28, 2026 /PRNewswire/ — Castlight Health, a leader […]
dōTERRA Welcomes Jeff Singer as New Chief Operating Officer
Experienced global leader joins dōTERRA executive team PLEASANT GROVE, Utah, July 6, 2023 /PRNewswire/ — dōTERRA, an integrative health and wellness company and world leader in the global aromatherapy and essential oils market, is pleased […]
BUCKED UP LAUNCHES FIRST-OF-ITS KIND ‘PIXIE PUMP’ PRE-WORKOUT
The Explosive Twist on an American Classic Offers Customers the Quickest Way to Get Bucked Up With No Liquid Required OREM, Utah, April 13, 2023 /PRNewswire/ — Sports nutrition and lifestyle brand Bucked Up today […]
